| Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease CC Bell, DFG Hendriks, SML Moro, E Ellis, J Walsh, A Renblom, ... Scientific reports 6 (1), 25187, 2016 | 660 | 2016 |
| Worldwide distribution of cytochrome P450 alleles: a meta‐analysis of population‐scale sequencing projects Y Zhou, M Ingelman‐Sundberg, VM Lauschke Clinical Pharmacology & Therapeutics 102 (4), 688-700, 2017 | 553 | 2017 |
| Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients J Stebbing, V Krishnan, S de Bono, S Ottaviani, G Casalini, ... EMBO molecular medicine 12 (8), e12697, 2020 | 284 | 2020 |
| Comparison of hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity applications: a multicenter study CC Bell, ACA Dankers, VM Lauschke, R Sison-Young, R Jenkins, ... Toxicological Sciences 162 (2), 655-666, 2018 | 272 | 2018 |
| Novel 3D culture systems for studies of human liver function and assessments of the hepatotoxicity of drugs and drug candidates VM Lauschke, DFG Hendriks, CC Bell, TB Andersson, ... Chemical research in toxicology 29 (12), 1936-1955, 2016 | 242 | 2016 |
| Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response M Kozyra, M Ingelman-Sundberg, VM Lauschke Genetics in Medicine 19 (1), 20-29, 2017 | 222 | 2017 |
| Scaling of embryonic patterning based on phase-gradient encoding VM Lauschke, CD Tsiairis, P François, A Aulehla Nature 493 (7430), 101-105, 2013 | 199 | 2013 |
| Integrating rare genetic variants into pharmacogenetic drug response predictions M Ingelman-Sundberg, S Mkrtchian, Y Zhou, VM Lauschke Human genomics 12, 1-12, 2018 | 198 | 2018 |
| JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality J Stebbing, G Sánchez Nievas, M Falcone, S Youhanna, P Richardson, ... Science advances 7 (1), eabe4724, 2021 | 197 | 2021 |
| Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting LV Kalman, JAG Agúndez, ML Appell, JL Black, GC Bell, S Boukouvala, ... Clinical Pharmacology & Therapeutics 99 (2), 172-185, 2016 | 190 | 2016 |
| A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study JJ Swen, CH van der Wouden, LEN Manson, H Abdullah-Koolmees, ... The Lancet 401 (10374), 347-356, 2023 | 173 | 2023 |
| Transcriptional, functional, and mechanistic comparisons of stem cell–derived hepatocytes, HepaRG cells, and three-dimensional human hepatocyte spheroids as predictive in vitro … CC Bell, VM Lauschke, SU Vorrink, H Palmgren, R Duffin, TB Andersson, ... Drug Metabolism and Disposition 45 (4), 419-429, 2017 | 173 | 2017 |
| Modulation of phase shift between Wnt and Notch signaling oscillations controls mesoderm segmentation KF Sonnen, VM Lauschke, J Uraji, HJ Falk, Y Petersen, MC Funk, ... Cell 172 (5), 1079-1090. e12, 2018 | 169 | 2018 |
| Prediction of drug-induced hepatotoxicity using long-term stable primary hepatic 3D spheroid cultures in chemically defined conditions SU Vorrink, Y Zhou, M Ingelman-Sundberg, VM Lauschke Toxicological Sciences 163 (2), 655-665, 2018 | 166 | 2018 |
| Endogenous and xenobiotic metabolic stability of primary human hepatocytes in long-term 3D spheroid cultures revealed by a combination of targeted and untargeted metabolomics SU Vorrink, S Ullah, S Schmidt, J Nandania, V Velagapudi, O Beck, ... The FASEB Journal 31 (6), 2696, 2017 | 150 | 2017 |
| Human hepatic 3D spheroids as a model for steatosis and insulin resistance M Kozyra, I Johansson, Å Nordling, S Ullah, VM Lauschke, ... Scientific reports 8 (1), 14297, 2018 | 147 | 2018 |
| Genetic variation in the human cytochrome P450 supergene family K Fujikura, M Ingelman-Sundberg, VM Lauschke Pharmacogenetics and genomics 25 (12), 584-594, 2015 | 138 | 2015 |
| Pharmacogenomic biomarkers for improved drug therapy—recent progress and future developments VM Lauschke, L Milani, M Ingelman-Sundberg The AAPS journal 20, 1-16, 2018 | 133 | 2018 |
| 3D primary hepatocyte culture systems for analyses of liver diseases, drug metabolism, and toxicity: emerging culture paradigms and applications VM Lauschke, RZ Shafagh, DFG Hendriks, M Ingelman‐Sundberg Biotechnology journal 14 (7), 1800347, 2019 | 123 | 2019 |
| An optimized prediction framework to assess the functional impact of pharmacogenetic variants Y Zhou, S Mkrtchian, M Kumondai, M Hiratsuka, VM Lauschke The pharmacogenomics journal 19 (2), 115-126, 2019 | 119 | 2019 |
Magnus Ingelman-SundbergKarolinska InstitutetGeverifieerd e-mailadres voor ki.se
